These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36355775)

  • 1. Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.
    Coccia M; Burny W; Demoitié MA; Gillard P; van den Berg RA; van der Most R
    PLoS One; 2022; 17(11):e0276505. PubMed ID: 36355775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
    Montoya J; Solon JA; Cunanan SR; Acosta L; Bollaerts A; Moris P; Janssens M; Jongert E; Demoitié MA; Mettens P; Gatchalian S; Vinals C; Cohen J; Ofori-Anyinam O
    J Clin Immunol; 2013 Nov; 33(8):1360-75. PubMed ID: 24142232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
    Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
    AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
    Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
    Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01.
    Ouaked N; Demoitié MA; Godfroid F; Mortier MC; Vanloubbeeck Y; Temmerman ST
    Tuberculosis (Edinb); 2023 Dec; 143():102425. PubMed ID: 38180028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant system AS01: from mode of action to effective vaccines.
    Roman F; Burny W; Ceregido A; Laupèze B; Temmerman ST; Warter L; Coccia M
    Expert Rev Vaccines; 2024 Jul; ():. PubMed ID: 39042099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
    Day CL; Tameris M; Mansoor N; van Rooyen M; de Kock M; Geldenhuys H; Erasmus M; Makhethe L; Hughes EJ; Gelderbloem S; Bollaerts A; Bourguignon P; Cohen J; Demoitié MA; Mettens P; Moris P; Sadoff JC; Hawkridge A; Hussey GD; Mahomed H; Ofori-Anyinam O; Hanekom WA
    Am J Respir Crit Care Med; 2013 Aug; 188(4):492-502. PubMed ID: 23306546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
    Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
    Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
    Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
    Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.
    Kumarasamy N; Poongulali S; Bollaerts A; Moris P; Beulah FE; Ayuk LN; Demoitié MA; Jongert E; Ofori-Anyinam O
    Medicine (Baltimore); 2016 Jan; 95(3):e2459. PubMed ID: 26817879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
    Folschweiller N; Vanden Abeele C; Chu L; Van Damme P; García-Sastre A; Krammer F; Nachbagauer R; Palese P; Solórzano A; Bi D; David MP; Friel D; Innis BL; Koch J; Mallett CP; Rouxel RN; Salaun B; Vantomme V; Verheust C; Struyf F
    Lancet Infect Dis; 2022 Jul; 22(7):1062-1075. PubMed ID: 35461522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials.
    Wilson L; Gracie L; Kidy F; Thomas GN; Nirantharakumar K; Greenfield S; Manaseki-Holland S; Ward DJ; Gooden TE
    BMC Infect Dis; 2023 Feb; 23(1):120. PubMed ID: 36829123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis vaccines: Opportunities and challenges.
    Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
    Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
    Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
    Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of specific humoral immune response and cross reactivity against Mycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis.
    de los Angeles García M; Borrero R; Marrón R; Lanio ME; Canet L; Otero O; Kadir R; Suraiya S; Zayas C; López Y; Nor Norazmi M; Sarmiento ME; Acosta A
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S11. PubMed ID: 23458421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.